ArticleCancers2025

First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.

Simone Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.